Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Short Interest Update

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) was the recipient of a large decline in short interest in March. As of March 31st, there was short interest totalling 5,280,000 shares, a decline of 5.9% from the March 15th total of 5,610,000 shares. Based on an average daily volume of 1,200,000 shares, the short-interest ratio is currently 4.4 days.

Hedge Funds Weigh In On Alpine Immune Sciences

Several institutional investors have recently bought and sold shares of the company. Banque Cantonale Vaudoise purchased a new position in Alpine Immune Sciences in the first quarter valued at approximately $798,000. HighPoint Advisor Group LLC purchased a new stake in shares of Alpine Immune Sciences during the fourth quarter worth $290,000. Vanguard Group Inc. lifted its position in shares of Alpine Immune Sciences by 51.5% during the fourth quarter. Vanguard Group Inc. now owns 2,234,767 shares of the biotechnology company’s stock worth $42,595,000 after acquiring an additional 759,888 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Alpine Immune Sciences by 176.6% during the fourth quarter. Wellington Management Group LLP now owns 109,882 shares of the biotechnology company’s stock worth $2,094,000 after acquiring an additional 70,151 shares in the last quarter. Finally, American International Group Inc. lifted its position in shares of Alpine Immune Sciences by 2.2% during the fourth quarter. American International Group Inc. now owns 16,185 shares of the biotechnology company’s stock worth $308,000 after acquiring an additional 343 shares in the last quarter. Hedge funds and other institutional investors own 75.17% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on ALPN. Oppenheimer reissued an “outperform” rating and set a $44.00 price objective (up from $33.00) on shares of Alpine Immune Sciences in a report on Tuesday, March 19th. Morgan Stanley reissued an “equal weight” rating and set a $65.00 price objective (up from $47.00) on shares of Alpine Immune Sciences in a report on Thursday, April 11th. HC Wainwright lowered Alpine Immune Sciences from a “buy” rating to a “neutral” rating in a report on Thursday, April 11th. Leerink Partnrs lowered Alpine Immune Sciences from an “outperform” rating to a “market perform” rating in a report on Thursday, April 11th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $65.00 target price (up from $41.00) on shares of Alpine Immune Sciences in a report on Thursday, April 11th. Eight investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Alpine Immune Sciences presently has a consensus rating of “Hold” and a consensus price target of $50.33.

Alpine Immune Sciences Trading Up 0.1 %

Alpine Immune Sciences stock opened at $64.50 on Wednesday. Alpine Immune Sciences has a 12 month low of $6.71 and a 12 month high of $64.57. The business’s 50 day simple moving average is $37.92 and its 200 day simple moving average is $23.86. The company has a market cap of $4.23 billion, a price-to-earnings ratio of -100.78 and a beta of 1.14.

Alpine Immune Sciences (NASDAQ:ALPN) last posted its quarterly earnings data on Monday, March 18th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of ($0.32) by $0.47. Alpine Immune Sciences had a negative return on equity of 15.54% and a negative net margin of 54.66%. The business had revenue of $30.85 million for the quarter, compared to the consensus estimate of $6.90 million. As a group, equities research analysts forecast that Alpine Immune Sciences will post -1.74 earnings per share for the current fiscal year.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.